Loading clinical trials...

Fatty Liver and Ectopic Fat in Overweight and Obese Patients | Clinical Trials | Clareo Health

COMPLETEDNA

Fatty Liver and Ectopic Fat in Overweight and Obese Patients

NCT00886301•Centre Hospitalier Universitaire de Nice

Summary

The aim of the study is to find new clinico-biological and medical imaging parameters associated with non alcoholic steatohepatitis in overweight and obese patients.

Detailed Description

Non invasive assessment of liver fibrosis and liver inflammation and steatosis is clinically relevant in patients exposed to non alcoholic fatty liver diseases. The aim of the study is to find new clinico-biological and medical imaging parameters associated with non alcoholic steatohepatitis in overweight and obese patients. Fatty liver and ectopic fat accumulation will be particularly assessed.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•BMI between 25 and 40
•ALAT level superior to normal level even after 3 months of diet
•alcohol consumption \< 20 g/j for women and \< 30 g/j for men

Exclusion Criteria

•HIV, hepatitis B virus, hepatitis C virus positive
•known hemochromatosis
•glycemia \> 1.26 g/L or under anti-diabetic treatment

Locations (1)

Hepatogastroenterology, Hôpital l'Archet, CHU de Nice

Nice, France

Key Dates

Start Date

March 1, 2010

Primary Completion Date

October 2, 2014

Completion Date

October 2, 2014

Last Updated

November 13, 2023

Enrollment

ACTUAL participants

Conditions

Steatohepatitis

Interventions

liver biopsy

PROCEDURE

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444

Metabolic Dysfunction Associated Steatohepatitis (MASH)Liver Fibrosis

View study

RECRUITING

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

NCT02815891

Nonalcoholic Fatty LiverNonalcoholic Steatohepatitis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 13, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Fatty Liver and Ectopic Fat in Overweight and Obese Patients

Inclusion Criteria

Exclusion Criteria

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Identification of Liver Fibrosis Biomarkers

Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA

Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis

Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients